Matthew Ruth brings significant commercial experience to Opiant. Matt served as SVP and Chief Commercial Officer at Adapt Pharma Ltd, where he led the launch and commercialization of the first nasal naloxone spray approved by the U.S. Food and Drug Administration to treat opioid overdose. Prior to his work in the opioid overdose space, Matt was Chief Operating Officer for RightCare Solutions, a medical technology company, where he built their commercial infrastructure and was instrumental in building a revenue stream that enabled their acquisition by NaviHealth in 2015. Before that, Matt was Vice President of Azur Pharma, responsible for the CNS franchise which was acquired by Jazz Pharmaceuticals. Earlier in his career, Matt worked at Avanir Pharmaceuticals and Allergan.